PMEF
CUE icon

Point72 Middle East FZE’s Cue Biopharma CUE Stock Holding History

Point72 Middle East FZE’s Portfolio CUE Stock Details CUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-22
Closed -$2.31K – 1640
2023
Q1 		$2.31K Buy
+22
New +$2.1K ﹤0.01% 1537

Other funds holding CUE

SPC
Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
RSWM
Robertson Stephens Wealth Management San Francisco, California $3.57B AUM 28.36% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return
MAM
Monaco Asset Management Monaco $542M AUM 54.4% 1-Year Est. Return

Point72 Middle East FZE's CUE Position: Q2 2023 in Review

Point72 Middle East FZE sold out of Cue Biopharma (CUE) in Q2 2023, closing a stake of 22 shares — an estimated $2.31K sold.

Point72 Middle East FZE first reported a position in CUE in Q1 2023 and held it in 1 quarter. The position peaked at $2.31K in Q1 2023. 78 funds tracked by Wall St. Rank hold CUE as of Q2 2023.

  • Point72 Middle East FZE reported no remaining Cue Biopharma position as of Q2 2023 after selling out during the quarter.
  • Point72 Middle East FZE sold 22 Cue Biopharma shares in Q2 2023, an estimated $2.31K.
  • Point72 Middle East FZE first reported a position in Cue Biopharma in Q1 2023 and held it in 1 quarter.
  • Point72 Middle East FZE's Cue Biopharma position peaked at $2.31K in Q1 2023.
  • 78 funds tracked by Wall St. Rank held Cue Biopharma as of Q2 2023.

Based on Point72 Middle East FZE's 13F filing for Q2 2023, filed 14 Aug 2023.